AffyMax

Affymax, Inc. is a biopharmaceutical company based in New York, founded in 2001, that focuses on developing novel peptide-based therapeutics aimed at treating serious and life-threatening conditions. The company's primary product, OMONTYS, is an injection designed to treat anemia associated with chronic kidney disease in adult patients on dialysis. OMONTYS is notable for being the only once-monthly erythropoiesis-stimulating agent available for this patient population in the United States. At one point, a New Drug Application for peginesatide, the active component of OMONTYS, was under review by the U.S. Food and Drug Administration, but the company currently does not have significant operations.